Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Apr 18;104(8):614-21.
doi: 10.1093/jnci/djs167. Epub 2012 Apr 5.

Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS

Larissa Nekhlyudov  1 , Laurel A Habel, Ninah Achacoso, Inkyung Jung, Reina Haque, Laura C Collins, Stuart J Schnitt, Charles P Quesenberry Jr, Suzanne W Fletcher
Affiliations
Multicenter Study

Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS

Larissa Nekhlyudov et al. J Natl Cancer Inst. .

Abstract

Background: Breast-conserving surgery (BCS) is the most common treatment for ductal carcinoma in situ (DCIS); however, how often women experience subsequent diagnostic evaluations over time is not known.

Methods: We identified 2948 women with DCIS who were treated with BCS from 1990 to 2001 and followed for up to 10 years at three integrated health-care delivery systems. We calculated the percentages of diagnostic mammograms and ipsilateral invasive procedures following the initial breast excision to treat DCIS, estimated the 10-year cumulative incidence of these procedures, and determined hazard ratios for both types of procedures with Cox regression modeling. All statistical tests were two-sided.

Results: Over 10 years, 907 women (30.8%) had 1422 diagnostic mammograms and 1813 (61.5%) had 2305 ipsilateral invasive procedures. Diagnostic mammograms occurred in 7.3% of women in the first 6 months and continued at a median annual rate of 4.3%. Ipsilateral invasive procedures occurred in 51.5% of women in the first 6 months and continued at a median annual rate of 3.1%. The estimated 10-year cumulative risk of having at least one diagnostic mammogram after initial DCIS excision was 41.0% (95% confidence interval [CI] = 38.5% to 43.5%); at least one invasive procedure, 65.7% (95% CI = 63.7% to 67.8%); and either event, 76.1% (95% CI = 74.1% to 78.1%). Excluding events in the first 6 months following initial DCIS excision, corresponding risks were 36.4% (95% CI = 33.8% to 39.0%) for diagnostic mammograms, 30.4% (95% CI = 26.9% to 33.8%) for invasive procedures, and 49.5% (95% CI = 45.6% to 53.5%) for either event.

Conclusions: Women with DCIS treated with BCS continue to have diagnostic and invasive breast procedures in the conserved breast over an extended period. The frequency of ongoing diagnostic breast evaluations should be included in discussions about treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of at least one diagnostic mammogram, ipsilateral invasive procedure, recurrent DCIS, or invasive breast cancer in women over 10 years following DCIS excision. This approach estimates the risk of experiencing an event while taking into account the risk of experiencing the other events of interest during this period (17). A) Follow-up begins at the time of index DCIS excision. B) Follow-up begins 6 months after index DCIS excision. BCa = recurrent ipsilateral invasive breast cancer; DCIS = recurrent ipsilateral ductal carcinoma in situ; DM = diagnostic mammogram; IP = invasive procedure. DM/IP, dotted and dashed line; IP, bold dashed line; DM, dotted line; BCa, bold solid line; DCIS, light dashed line. All statistical tests were two-sided.
See this image and copyright information in PMC

Comment in

References

    1. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328(22):1581–1586. - PubMed
    1. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000. - PubMed
    1. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441–452. - PubMed
    1. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443–448. - PubMed
    1. Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG) Eur J Cancer. 1998;34(3):307–314. - PubMed

Publication types

MeSH terms